ongoing (>48 hours) or planned full-dose (therapeutic) anticoagulation for any indication ongoing or planned treatment with dual antiplatelet therapy contraindication to antithrombotic therapy or high risk of bleeding due to conditions including, but not limited to, any of the following: history of intracranial hemorrhage, known cns tumor or cns vascular abnormality active or recent major bleeding within the past 30 days with untreated source platelet count <70,000 or known functional platelet disorder fibrinogen <200 mg/dl international normalized ratio (inr) >1.9 history of heparin-induced thrombocytopenia ischemic stroke within the past 2 weeks patients who meet the following criterion are excluded from the second randomization (antiplatelet therapy vs. no antiplatelet therapy): 1. ongoing or planned antiplatelet therapy, including aspirin monotherapy

ongoing (>48 hours) or planned full-dose (therapeutic) anticoagulation for any indication ongoing or planned treatment with dual antiplatelet therapy contraindication to antithrombotic therapy or high risk of bleeding due to conditions including, but not limited to, any of the following: history of intracranial hemorrhage, known cns tumor or cns vascular abnormality active or recent major bleeding within the past 30 days with untreated source platelet count <70,000 or known functional platelet disorder fibrinogen <200 mg/dl international normalized ratio (inr) >1.9 history of heparin-induced thrombocytopenia ischemic stroke within the past 2 weeks patients who meet the following criterion are excluded from the second randomization (antiplatelet therapy vs. no antiplatelet therapy): 1. ongoing or planned antiplatelet therapy, including aspirin monotherapy

1. ongoing (>48 hours) or planned full-dose (therapeutic) anticoagulation for any indication 2. ongoing or planned treatment with dual antiplatelet therapy 3. contraindication to antithrombotic therapy or high risk of bleeding due to conditions including, but not limited to, any of the following: 1. history of intracranial hemorrhage, known cns tumor or cns vascular abnormality 2. active or recent major bleeding within the past 30 days with untreated source 3. platelet count <70,000 or known functional platelet disorder 4. fibrinogen <200 mg/dl 5. international normalized ratio (inr) >1.9 4. history of heparin-induced thrombocytopenia 5. ischemic stroke within the past 2 weeks patients who meet the following criterion are excluded from the second randomization (antiplatelet therapy vs. no antiplatelet therapy): 1. ongoing or planned antiplatelet therapy, including aspirin monotherapy

1. ongoing (>48 hours) or planned full-dose (therapeutic) anticoagulation for any indication 2. ongoing or planned treatment with dual antiplatelet therapy 3. contraindication to antithrombotic therapy or high risk of bleeding due to conditions including, but not limited to, any of the following: 1. history of intracranial hemorrhage, known cns tumor or cns vascular abnormality 2. active or recent major bleeding within the past 30 days with untreated source 3. platelet count <70,000 or known functional platelet disorder 4. fibrinogen <200 mg/dl 5. international normalized ratio (inr) >1.9 4. history of heparin-induced thrombocytopenia 5. ischemic stroke within the past 2 weeks patients who meet the following criterion are excluded from the second randomization (antiplatelet therapy vs. no antiplatelet therapy): 1. ongoing or planned antiplatelet therapy, including aspirin monotherapy